Maxim Group Downgrades Gilead Sciences(GILD.US) to Hold Rating

Maxim Group下調吉利德科學(GILD.US)至持有評級

moomoo資訊 · 2024/11/08 14:32 · 評級/大行評級

Maxim Group analyst Michael Okunewitch downgrades $Gilead Sciences (GILD.US)$ to a hold rating.

According to TipRanks data, the analyst has a success rate of 34.0% and a total average return of -14.6% over the past year.

AnalystRecentRatingAutoNews_206491_20241108_0dd1f8b743a0f68b955520163d11569133615389_1731144688256413_mm_en

Furthermore, according to the comprehensive report, the opinions of $Gilead Sciences (GILD.US)$'s main analysts recently are as follows:

Gilead's recent financial results exceeded sales expectations, bolstered by robust performance within its HIV product lineup and higher than anticipated revenues from Veklury. The company's HIV segment experienced a solid quarter marked by ongoing volume increases and a positive product mix.
The company's third-quarter performance surpassed expectations, bolstered not only by Veklury but by Biktarvy as well.
The sentiment is that significant changes are underway for the company, as it shifts away from past business development decisions and refocuses on its core strength in antiviral innovation. The introduction of lenacapavir is anticipated to have a dual role, acting as a next-generation foundation for HIV treatment and potentially broadening the scope of PrEP to a wider audience. There's a belief that the PrEP market holds potential for expansion beyond the traditional high-risk demographics. In the oncology space, there's notable progress, with TRODELVY experiencing double-digit growth and a promising partnership that could lead to a leading CAR-T therapy for multiple myeloma.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

Maxim Group分析師Michael Okunewitch下調$吉利德科學 (GILD.US)$至持有評級。

根據TipRanks數據顯示，該分析師近一年總勝率為34.0%，總平均回報率為-14.6%。

AnalystRecentRatingAutoNews_206491_20241108_0dd1f8b743a0f68b955520163d11569133615389_1731144688256413_mm_tc

此外，綜合報道，$吉利德科學 (GILD.US)$近期主要分析師觀點如下：

吉利德最近的財務業績超出了銷售預期，這得益於其HIV產品陣容的強勁表現以及Veklury高於預期的收入。該公司的HIV板塊經歷了穩健的季度業績，其特點是銷量持續增長，產品組合良好。
該公司第三季度的業績超出了預期，這不僅得到了Veklury的支持，也得到了Biktarvy的推動。
人們認爲，隨着公司擺脫過去的業務發展決策，將重點重新放在抗病毒創新方面的核心優勢上，該公司正在發生重大變化。預計來那卡韋的推出將起到雙重作用，既是HIV治療的下一代基礎，又有可能將PrEP的範圍擴大到更廣泛的受衆。人們認爲，PrEP市場具有超越傳統高風險人群的擴張潛力。在腫瘤學領域，取得了顯著進展，TRODELVY實現了兩位數的增長，合作前景光明，這可能會導致領先的多發性骨髓瘤CAR-T療法。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Maxim Group Downgrades Gilead Sciences(GILD.US) to Hold Rating

Maxim Group Downgrades Gilead Sciences(GILD.US) to Hold Rating

風險及免責聲明

聲明